Humanigen (OTCQB: HGEN) CEO Durrant joined Steve Darling from Proactive in Vancouver to discuss the company that it is actively exploring clinical-stage strategies and partnerships to evaluate whether "lenzilumab", the company’s proprietary monoclonal antibody, may reduce or prevent cytokine storm resulting from COVID-19 infection.
Durrant talked about cytokine storms and their relation to a virus like Corona.
Add related topics to MyProactive
Create your account: sign up and get ahead on news and events
NO INVESTMENT ADVICE
The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...
In exchange for publishing services rendered by the Company on behalf of Humanigen, Inc. named herein, including the promotion by the Company of Humanigen, Inc. in any Content on the Site, the Company receives from...
FOR OUR FULL DISCLAIMER CLICK HERE